Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-613 with Metformin in Relapsed/Refractory AML
NCT05854966Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of devimistat in acute myeloid leukemia (AML), granulocytic sarcoma (MS), sponsored by Wake Forest University Health Sciences. Planned start Dec 2024; status: withdrawn.
02
Drugs
devimistat
03
Conditions
acute myeloid leukemia (AML)granulocytic sarcoma (MS)
Beyond the preview
Go deeper on NCT05854966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05854966.